CY1111596T1 - Υποκατεστημενες ακετοφαινονες χρησιμες ως αναστολεις pde4 - Google Patents
Υποκατεστημενες ακετοφαινονες χρησιμες ως αναστολεις pde4Info
- Publication number
- CY1111596T1 CY1111596T1 CY20111100615T CY111100615T CY1111596T1 CY 1111596 T1 CY1111596 T1 CY 1111596T1 CY 20111100615 T CY20111100615 T CY 20111100615T CY 111100615 T CY111100615 T CY 111100615T CY 1111596 T1 CY1111596 T1 CY 1111596T1
- Authority
- CY
- Cyprus
- Prior art keywords
- represent
- independently
- pde4 inhibitors
- haloalkyl
- hydroxyalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Η παρούσα εφεύρεση αφορά ένωση σύμφωνα με τον τύπο: (I), όπου τα Χ1, Χ2, Χ3, Χ4 και Χ5 ανεξαρτήτως το ένα από το άλλο αντιπροσωπεύουν -CH- ή Ν, ή τα Χ3, Χ4 και Χ5 ανεξαρτήτως το ένα από το άλλο αντιπροσωπεύουν -CH- ή Ν, και τα Χ1 και Χ2 ανεξαρτήτως το ένα από το άλλο αντιπροσωπεύουν C και σχηματίζουν τμήμα ενός επιπλέον 6-μελούς αρωματικού δακτυλίου, το R1 αντιπροσωπεύει υδρογόνο, αλκυλ, αλκενυλ, αλκυνυλ, αλογονοαλκυλ, υδροξυαλκυλ, ή αλκυλκαρβονυλ, όλα από τα οποία είναι προαιρετικώς υποκατεστημένα, τα R2 και R3 ανεξαρτήτως αντιπροσωπεύουν υδρογόνο, -CH2-C(O)NR-R', αλκυλ, κυκλοαλκυλ, αλκενυλ, κυκλοαλκενυλ, αλκυνυλ, αλογονοαλκυλ, υδροξυαλκυλ, ετεροκυκλοαλκενυλ, αλκυλαρυλ, αρυλαλκυλ, αλκυλαλκοξυκαρβονυλ, αλκυλκαρβονυλοξυ, ή αλκοξυαλκυλ, όλα από τα οποία είναι προαιρετικώς υποκατεστημένα, το R11 αντιπροσωπεύει υδρογόνο, αλογόνο, κυανό, αμινο, αλκοξυ ή αλκυλαμινο, τα Χ1-Χ5 αντιπροσωπεύουν -CH- ή Ν, συμπεριλαμβανομένων Ν-οξειδίων, εναντιομερών και διαστερεομερών, και φαρμακευτικώς αποδεκτά άλατα, υδρίτες, ή διαλυτώματα αυτών. Η εφεύρεση περαιτέρω αφορά διεργασίες για την παρασκευή των εν λόγω ενώσεων, τις εν λόγω ενώσεις για χρήση στη θεραπεία, φαρμακευτικές συνθέσεις που περιλαμβάνουν τις εν λόγω ενώσεις, μεθόδους θεραπείας ασθενειών, π.χ., δερματικών ασθενειών, με τις εν λόγω ενώσεις, και τη χρήση των εν λόγω ενώσεων στην κατασκευή φαρμάκων.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87168906P | 2006-12-22 | 2006-12-22 | |
US94547007P | 2007-06-21 | 2007-06-21 | |
EP07846434A EP2125736B1 (en) | 2006-12-22 | 2007-12-21 | Substituted acetophenones useful as pde4 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1111596T1 true CY1111596T1 (el) | 2015-10-07 |
Family
ID=39156588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20111100615T CY1111596T1 (el) | 2006-12-22 | 2011-06-28 | Υποκατεστημενες ακετοφαινονες χρησιμες ως αναστολεις pde4 |
Country Status (24)
Country | Link |
---|---|
US (3) | US8148537B2 (el) |
EP (1) | EP2125736B1 (el) |
JP (1) | JP5342451B2 (el) |
KR (1) | KR101507717B1 (el) |
AT (1) | ATE503742T1 (el) |
AU (1) | AU2007336538B2 (el) |
BR (1) | BRPI0721113A2 (el) |
CA (1) | CA2673370C (el) |
CR (1) | CR10877A (el) |
CY (1) | CY1111596T1 (el) |
DE (1) | DE602007013617D1 (el) |
DK (1) | DK2125736T3 (el) |
GT (1) | GT200900172A (el) |
HK (1) | HK1135392A1 (el) |
HR (1) | HRP20110464T1 (el) |
IL (1) | IL199383A (el) |
MX (1) | MX2009006593A (el) |
MY (1) | MY146022A (el) |
NO (1) | NO20092372L (el) |
NZ (1) | NZ577863A (el) |
PL (1) | PL2125736T3 (el) |
PT (1) | PT2125736E (el) |
RU (1) | RU2493149C2 (el) |
WO (1) | WO2008077404A1 (el) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2012007229A (es) | 2009-12-22 | 2012-07-30 | Leo Pharma As | Composicion cutanea que comprende analogo de vitamina d y mezcla de solvente y tensioactivos. |
US20130023501A1 (en) | 2009-12-22 | 2013-01-24 | Leo Pharma A/S | Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue |
CA2785253A1 (en) | 2009-12-22 | 2011-06-30 | Leo Pharma A/S | Calcipotriol monohydrate nanocrystals |
CN102775345A (zh) * | 2011-05-13 | 2012-11-14 | 上海特化医药科技有限公司 | 制备罗氟司特的方法及中间体 |
RU2663448C2 (ru) * | 2012-11-30 | 2018-08-06 | Лео Фарма А/С | Способ ингибирования экспрессии ил-22 активированными т-клетками |
WO2014096018A1 (en) * | 2012-12-19 | 2014-06-26 | Leo Pharma A/S | Methods for the preparation of substituted acetophenones |
EP4059921A1 (en) | 2013-10-22 | 2022-09-21 | Chiesi Farmaceutici S.p.A. | Process for the preparation of a pde4 inhibitor |
BR112016029510A2 (pt) | 2014-06-23 | 2017-08-22 | Leo Pharma As | métodos para a preparação de um composto, e, composto intermediário. |
WO2017089347A1 (en) | 2015-11-25 | 2017-06-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas |
DK3390407T3 (da) | 2015-12-18 | 2023-11-06 | Union Therapeutics As | Fremgangsmåder til fremstilling af heterocykliske 1,3-benzodioxolforbindelser |
KR101702648B1 (ko) * | 2016-05-10 | 2017-02-03 | 주식회사 엑티브온 | 피부 외용제용 보존제, 이를 포함하는 화장료 조성물 및 약학 조성물 |
BR112019025028A2 (pt) | 2017-06-20 | 2020-06-16 | Leo Pharma A/S | Método para preparar um composto. |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW263495B (el) * | 1992-12-23 | 1995-11-21 | Celltech Ltd | |
GB9401460D0 (en) * | 1994-01-26 | 1994-03-23 | Rhone Poulenc Rorer Ltd | Compositions of matter |
DE69636086T2 (de) * | 1995-05-19 | 2006-11-30 | Kyowa Hakko Kogyo Co., Ltd. | Sauerstoff enthaltende heterocyclische verbindungen |
US6514996B2 (en) * | 1995-05-19 | 2003-02-04 | Kyowa Hakko Kogyo Co., Ltd. | Derivatives of benzofuran or benzodioxole |
EP0943613A4 (en) * | 1996-11-19 | 2002-07-10 | Kyowa Hakko Kogyo Kk | HETEROCYCLIC COMPOUNDS CONTAINING OXYGEN |
WO2004082683A1 (ja) * | 2003-03-17 | 2004-09-30 | Kyowa Hakko Kogyo Co., Ltd. | 慢性皮膚疾患の治療および/または予防剤 |
WO2006040645A1 (en) * | 2004-10-11 | 2006-04-20 | Ranbaxy Laboratories Limited | N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma |
CA2611562A1 (en) * | 2005-06-10 | 2006-12-21 | Memory Pharmaceuticals Corporation | Trisubstituted amines as phosphodiesterase 4 inhibitors |
-
2007
- 2007-12-21 NZ NZ577863A patent/NZ577863A/en not_active IP Right Cessation
- 2007-12-21 CA CA2673370A patent/CA2673370C/en not_active Expired - Fee Related
- 2007-12-21 AU AU2007336538A patent/AU2007336538B2/en not_active Ceased
- 2007-12-21 KR KR1020097015481A patent/KR101507717B1/ko active IP Right Grant
- 2007-12-21 DK DK07846434.4T patent/DK2125736T3/da active
- 2007-12-21 PL PL07846434T patent/PL2125736T3/pl unknown
- 2007-12-21 PT PT07846434T patent/PT2125736E/pt unknown
- 2007-12-21 US US12/520,325 patent/US8148537B2/en not_active Expired - Fee Related
- 2007-12-21 RU RU2009128191/04A patent/RU2493149C2/ru not_active IP Right Cessation
- 2007-12-21 MY MYPI20092592A patent/MY146022A/en unknown
- 2007-12-21 WO PCT/DK2007/000564 patent/WO2008077404A1/en active Application Filing
- 2007-12-21 MX MX2009006593A patent/MX2009006593A/es active IP Right Grant
- 2007-12-21 EP EP07846434A patent/EP2125736B1/en active Active
- 2007-12-21 AT AT07846434T patent/ATE503742T1/de active
- 2007-12-21 JP JP2009541766A patent/JP5342451B2/ja not_active Expired - Fee Related
- 2007-12-21 DE DE602007013617T patent/DE602007013617D1/de active Active
- 2007-12-21 BR BRPI0721113-9A2A patent/BRPI0721113A2/pt not_active Application Discontinuation
-
2009
- 2009-06-16 IL IL199383A patent/IL199383A/en active IP Right Grant
- 2009-06-19 GT GT200900172A patent/GT200900172A/es unknown
- 2009-06-19 CR CR10877A patent/CR10877A/es unknown
- 2009-06-22 NO NO20092372A patent/NO20092372L/no not_active Application Discontinuation
-
2010
- 2010-02-25 HK HK10102008.4A patent/HK1135392A1/xx not_active IP Right Cessation
-
2011
- 2011-06-20 HR HR20110464T patent/HRP20110464T1/hr unknown
- 2011-06-28 CY CY20111100615T patent/CY1111596T1/el unknown
-
2012
- 2012-02-28 US US13/406,932 patent/US8324394B2/en not_active Expired - Fee Related
- 2012-07-11 US US13/546,758 patent/US8497380B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1111596T1 (el) | Υποκατεστημενες ακετοφαινονες χρησιμες ως αναστολεις pde4 | |
NO20063129L (no) | Substituerte 6-cykloheksylalkylsubstituerte 2-kinolinoner og 2-kinoksalinoner som poly(ADP-ribose) polymeraseinhibitorer | |
NO20063028L (no) | 6-substituerte 2-kinolinoner og 2-kinoksalinoner som poly(adp-ribose)-polymeraseinhibitorer | |
NO20062892L (no) | 7-fenylalkyl-substituert 2-kinolinoner og 2-kinoksalinoner som poly(adp-ribose)-polymeraseinhibitorer | |
NO20070532L (no) | Substituerte 2-alkyl-kinazolinonderivater som PARP-inhibitorer | |
UA115666C2 (uk) | Заміщена оксимом амідна сполука і засіб для боротьби зі шкідниками | |
NO20062894L (no) | 6-alkenyl og 6-fenylalkylsubstituert 2-kinolinoner og 2-kinoksalinoner som poly(adp-ribose)polymeraseinhibitorer | |
WO2007071632A3 (en) | 2-pyridin-2-yl-quinazoline derivatives as potassium channel modulating agents for the treatment of respiratory diseases | |
HK1099235A1 (en) | Phosphonate analogs of hiv integrase inhibitor compounds hiv | |
EA200870321A1 (ru) | Способ получения 4-оксохинолинового соединения | |
ZA200810739B (en) | Pesticide containing novel pyridyl-methanamine derivative or its salt | |
NO20076145L (no) | Ureadeviater, fremgangsmater for deres fremstilling og anvendelse derav | |
EA201101334A1 (ru) | Новые соединения бензотиадиазепина, способ их приготовления и фармацевтические композиции, содержащие их | |
TW200738145A (en) | Pesticidal mixtures | |
TW200716571A (en) | Heterocyclic reverse transcriptase inhibitors | |
TW200735779A (en) | Pesticidal mixtures | |
UA96783C2 (ru) | Замещенные метилфенилкетоны, пригодные для использования как ингибиторы pde4 | |
DK1628968T3 (da) | 4-imidazolin-2-on-forbindelser | |
TW200740757A (en) | Carboxamide compound and use of the same | |
TW200612944A (en) | 4-(2,4-dichloro-5-methoxyphenyl)amino-6-methoxy-7-{[5-(substituted-amino)methyl]-3-furyl}-3-quinolinecarbonitriles as kinase inhibitors | |
TW200503733A (en) | T-shaped channel blockers | |
EA201290487A1 (ru) | 5-амино-4-гидроксипентоиламиды | |
SE0403003D0 (sv) | Chemical compound 1 | |
EA200970812A1 (ru) | Способ лечения и предупреждения артрита | |
TW200618797A (en) | Isatin compounds and pharmaceutical composition comprising the same |